Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

6-9 November, 2018
Postillion Convention Center,
Amsterdam, Netherlands

Increase half-life and minimise manufacturing costs through new data, case studies and technologies for peptide therapeutics

Accelerate your peptide therapeutics to market

Discovery & R&D
  • New frontiers in peptide therapeutics – Where are the future opportunities?
  • Explore the latest selection and screening technologies for lead discovery
  • Improve drug-like properties of next generation peptide therapeutics: Lead optimisation and engineering strategies
  • Implement cost of goods modelling to evaluate potential drug candidates
Delivery & Clinical Updates
  • What are the most exciting peptides advancing through the clinic?
  • Get top tips learnt from preclinical and clinical development
  • Examine the latest advances in oral peptide therapeutics
  • Stay on top of new techniques for improved administration of peptide products
Manufacturing & CMC
  • Delve into strategies to reduce cost of goods and improve manufacturing efficiency
  • Master process development and scale up of complex peptide therapeutics
  • Discover how enzymatic synthesis and continuous flow can be applied to large scale production
  • Uncover analytical methods to identify and characterise peptide impurities

NEW TOPICS AND INDUSTRY CASE STUDIES FOR 2018 FOCUSED ON:

  • Cost of Goods Modelling and Strategies to Evaluate Potential Drug Candidates
  • Enzymatic peptide synthesis
  • Non-Clinical Safety Assessment and Toxicology Programmes for Peptides
  • Large Scale Application of Continuous Manufacturing for Peptide Therapeutics
  •  Industry Applications of QbD and Risk Based Approaches for Peptide Therapeutics

TIDES DIGITAL WEEK


Join us 17-20 September 2018 for TIDES: Oligonucleotide & Peptide Therapeutics Digital Week: 4 days packed with webinars to help you stay current on the latest industry news and developments. And, it's completely free! Plus, get the questions answers to your toughest questions from our speakers during live Q&As. 

Interested in sponsorship opportunities? Partner your way to oligo and peptide therapeutic success by sponsoring TIDES: Oligonucleotide & Peptide Therapeutics Digital Week. Engage our digital oligo and peptide audience while generating leads, promoting your brand, and demonstrating your expertise.

To learn more about sponsorship opportunities, contact partners@knect365lifesciences.com or request sponsor details.

GAIN THE SCIENCE, TECHNOLOGIES AND CONTACTS YOU NEED TO ACCELERATE PEPTIDE THERAPEUTICS TO MARKET

300+
OLIGONUCLEOTIDE AND PEPTIDE SCIENTISTS AND EXECUTIVES
40+
CASE STUDIES AND NEW DATA PRESENTATIONS
30+
LEADING EXHIBITORS

Present a Scientific Poster


Share your company's new research by presenting a poster at TIDES 2018. All posters are displayed in the exhibit & poster hall area throughout the event.

Please note that all poster presenters must be registered attendees. The deadline for poster submissions is Friday, 5 October 2018.

Thank you to our EuroPEPTIDES 2018 Scientific Advisory Board

  • Waleed Danho, Former, Distinguished Research Leader, Roche, USA
  • Bruce Morimoto, Executive Director, Applied Translational Medicine, Celerion, USA
  • Thomas Meier, Chief Operations Officer, Bachem Europe, Switzerland
  • Jesper Lau, Vice President, Diabetes Protein & Peptide Chemistry, Novo Nordisk, Denmark
  • Joel Richard, Senior Vice President, Peptides - Head of CMC Development, Ipsen, France
  • Neil Thompson, Director Business Development, PolyPeptide
  • Leila Malik, CMC Project Manager, Zealand Pharma
  • Michael Postlethwaite, Program and Business Development Manager, Bachem, Switzerland

PARTNERING OPPORTUNITIES AT EuroPEPTIDES 2018


Highlight your company's expertise to 300+ scientists and key decision makers working across peptide & oligonucleotide development.  A wide variety of options are available to accommodate your company's goals and budget.